Boe Sandahl Sorensen

List of Publications by Year in Descending Order

88 papers	2,304 citations	25 h-index	45 g-index
92 ext. papers	2,683 ext. citations	4.5 avg, IF	4.92 L-index

#	Paper	IF	Citations
88	Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. *BMC Cancer*, **2021**, 21, 376	4.8	3
87	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. *Clinical Lung Cancer*, **2021**, 22, e870-e877	4.9	1
86	STAT3 is over-activated within CD163 bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	3
85	CELL-FREE DNA AND CLINICAL CHARACTERISTICS IN PATIENTS WITH SMALL INTESTINAL OR PANCREATIC NEUROENDOCRINE TUMORS. *Neuroendocrinology*, **2021**,	5.6	2
84	EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP). *Molecular Oncology*, **2021**, 15, 2868-2876	7.9	0
83	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. *Case Reports in Oncology*, **2021**, 14, 1323-1327	1	2
82	cGAS-STING pathway expression as a prognostic tool in NSCLC. *Translational Lung Cancer Research*, **2021**, 10, 340-354	4.4	2
81	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. *Cancers*, **2020**, 12,	6.6	3
80	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. *Lung Cancer*, **2020**, 143, 67-72	5.9	8
79	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. *Cancers*, **2020**, 12,	6.6	10
78	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. *Lung Cancer*, **2020**, 141, 37-43	5.9	10
77	Neurofilament Light Chain as A Biomarker for Brain Metastases. *Cancers*, **2020**, 12,	6.6	10
76	Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of -amplified EGFR-TKI resistant non-small cell lung cancer cells. *Translational Lung Cancer Research*, **2020**, 9, 1904-1914	4.4	2
75	Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients. *Lung Cancer*, **2020**, 147, 244-251	5.9	5
74	TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. *Scandinavian Journal of Gastroenterology*, **2020**, 55, 1433-1440	2.4	14
73	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. *Clinical Lung Cancer*, **2019**, 20, 161-166.e1	4.9	8
72	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. *Scientific Reports*, **2019**, 9, 11542	4.9	13

71	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. *Lung Cancer*, **2019**, 135, 92-96	5.9	14
70	Intra-individual variation of circulating tumour DNA in lung cancer patients. *Molecular Oncology*, **2019**, 13, 2098-2106	7.9	9
69	Day-to-day and within-day biological variation of cell-free DNA. *EBioMedicine*, **2019**, 49, 284-290	8.8	27
68	Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC. *Translational Oncology*, **2019**, 12, 432-440	4.9	11
67	The prognostic role of inflammation-scores on overall survival in lung cancer patients. *Acta Oncologica*, **2019**, 58, 371-376	3.2	9
66	Soluble HER3 predicts survival in bladder cancer patients. *Oncology Letters*, **2018**, 15, 1783-1788	2.6	4
65	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. *BMC Cancer*, **2018**, 18, 191	4.8	11
64	Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. *Journal of Molecular Diagnostics*, **2018**, 20, 483-494	5.1	19
63	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. *Translational Oncology*, **2018**, 11, 1220-1224	4.9	44
62	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. *Oncotarget*, **2018**, 9, 31066-31076	3.3	16
61	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. *Tumor Biology*, **2018**, 40, 1010428318811207	2.9	8
60	Increased PD-L1 expression in erlotinib-resistant NSCLC cells with gene amplification is reversed upon MET-TKI treatment. *Oncotarget*, **2017**, 8, 68221-68229	3.3	21
59	Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. *Tumor Biology*, **2017**, 39, 1010428317730976	2.9	12
58	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. *British Journal of Cancer*, **2017**, 117, 704-709	8.7	31
57	IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells. *Oncotarget*, **2017**, 8, 33300-33315	3.3	16
56	Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations. *Translational Oncology*, **2016**, 9, 306-12	4.9	7
55	Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1 down-regulation in metastatic cells. *BMC Cancer*, **2016**, 16, 32	4.8	8
54	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *Translational Lung Cancer Research*, **2016**, 5, 172-82	4.4	53

53	Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. *Stem Cells International*, **2016**, 2016, 9601493	5	11
52	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. *Translational Oncology*, **2016**, 9, 505-511	4.9	11
51	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2016**, 76, 243-8	2	2
50	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. *Lung Cancer*, **2016**, 94, 81-7	5.9	28
49	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. *Lung Cancer*, **2016**, 100, 77-84	5.9	70
48	Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 1701-10	8.3	154
47	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. *Lung Cancer*, **2015**, 90, 314-20	5.9	12
46	Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. *Journal of Extracellular Vesicles*, **2015**, 4, 26659	16.4	189
45	Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer. *BJU International*, **2015**, 115, 163-5	5.6	10
44	EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer. *Lung Cancer*, **2014**, 83, 224-30	5.9	33
43	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. *Lung Cancer*, **2014**, 85, 435-41	5.9	11
42	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. *BMC Cancer*, **2014**, 14, 294	4.8	116
41	Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. *PLoS ONE*, **2014**, 9, e94606	3.7	28
40	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. *Cancer*, **2014**, 120, 3896-901	6.4	151
39	Expression of the epidermal growth factor system in human middle ear cholesteatoma. *Acta Oto-Laryngologica*, **2014**, 134, 124-34	1.6	6
38	HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma. *Melanoma Research*, **2014**, 24, 88-91	3.3	13
37	The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor is not expressed. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2013**, 73, 503-13	2	5
36	Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases. *SpringerPlus*, **2013**, 2, 464		10

35	Estrogen receptor is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. *Breast Cancer Research and Treatment*, **2013**, 139, 71-80	4.4	55
34	Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. *PLoS ONE*, **2012**, 7, e40243	3.7	25
33	A single rainbow trout cobalamin-binding protein stands in for three human binders. *Journal of Biological Chemistry*, **2012**, 287, 33917-25	5.4	11
32	Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. *Journal of Thoracic Oncology*, **2011**, 6, 1287-9	8.9	98
31	Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib. *Journal of Thoracic Oncology*, **2011**, 6, 1946-9	8.9	10
30	Calcium-induced apoptosis is delayed by HER1 receptor signalling through the Akt and PLC pathways in bladder cancer cells. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2011**, 71, 45-51	2	1
29	Identifying responders to trastuzumab therapy in breast cancer. *Future Oncology*, **2011**, 7, 767-73	3.6	4
28	Mouse transcobalamin has features resembling both human transcobalamin and haptocorrin. *PLoS ONE*, **2011**, 6, e20638	3.7	25
27	Transcobalamin deficiency caused by compound heterozygosity for two novel mutations in the TCN2 gene: a study of two affected siblings, their brother, and their parents. *Journal of Inherited Metabolic Disease*, **2010**, 33 Suppl 3, S269-74	5.4	11
26	Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. *Anticancer Research*, **2010**, 30, 2463-8	2.3	15
25	Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. *Cancer Research*, **2009**, 69, 873-8	10.1	135
24	Expression of the epidermal growth factor system in eutopic endometrium from women with endometriosis differs from that in endometrium from healthy women. *Gynecologic and Obstetric Investigation*, **2009**, 67, 118-26	2.5	14
23	Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. *Breast Cancer Research and Treatment*, **2009**, 114, 263-75	4.4	111
22	A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. *Acta Oncologica*, **2008**, 47, 618-32	3.2	21
21	Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients. Detection of melanocytic mRNA predicts disease-free survival. *Apmis*, **2008**, 116, 199-205	3.4	6
20	Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. *BJU International*, **2007**, 99, 196-201	5.6	5
19	Expression of the epidermal growth factor system in endometrioid endometrial cancer. *Gynecologic Oncology*, **2007**, 104, 158-67	4.9	40
18	Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: identification of a specific insulin-responsive promoter element. *Biochemical and Biophysical Research Communications*, **2007**, 354, 885-91	3.4	17

17	The chemotherapeutic agent VP16 increases the stability of HB-EGF mRNA by a mechanism involving the 3SUTR. *Experimental Cell Research*, **2006**, 312, 3651-8	4.2	6
16	Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. *Journal of Clinical Oncology*, **2006**, 24, 798-804	2.2	68
15	Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system. *FEBS Journal*, **2006**, 273, 5479-89	5.7	15
14	Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma. *Journal of Investigative Dermatology*, **2006**, 126, 849-54	4.3	8
13	Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. *Melanoma Research*, **2005**, 15, 409-16	3.3	29
12	Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. *Prostate*, **2005**, 64, 1-8	4.2	15
11	Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA. *Clinical Cancer Research*, **2005**, 11, 1425-33	12.9	22
10	The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. *Molecular and Cellular Biochemistry*, **2004**, 260, 129-35	4.2	10
9	S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. *Melanoma Research*, **2004**, 14, 211-5	3.3	8
8	The influence of immunohistochemistry on mRNA recovery from microdissected frozen and formalin-fixed, paraffin-embedded sections. *Diagnostic Molecular Pathology*, **2004**, 13, 224-33		26
7	ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. *Prostate*, **2003**, 56, 142-9	4.2	34
6	Transcellular transport of vitamin B(12) in LLC-PK1 renal proximal tubule cells. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 1099-1106	12.7	23
5	Simultaneous quantitation of several mRNA species by calibrated reverse transcription polymerase chain reaction and capillary electrophoresis: analysis of the epidermal growth factor receptor and its activating ligands EGF, TGF-alpha, and HB-EGF in rat liver. *Laboratory Investigation*, **2000**, 80, 983-6	5.9	6
4	Quantitation of the mRNA expression of the epidermal growth factor system: selective induction of heparin-binding epidermal growth factor-like growth factor and amphiregulin expression by growth factor stimulation of prostate stromal cells. *Translational Research*, **2000**, 136, 209-17		13
3	Epidermal growth factor and insulin-like growth factor I upregulate the expression of the epidermal growth factor system in rat liver. *Journal of Hepatology*, **2000**, 32, 645-54	13.4	7
2	Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. *Biochemical Pharmacology*, **1993**, 45, 2025-35	6	59
1	Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). *Biochemical Pharmacology*, **1993**, 46, 389-93	6	75